---
title: "Why Is Regentis Biomaterials Stock Rising On Wednesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290071993.md"
description: "Regentis Biomaterials (RGNT) stock rose over 11% on Wednesday after the company withdrew its Form F-1 registration statement for a proposed $10 million public offering, eliminating immediate equity dilution. Additionally, the company accelerated commercialization plans for its CE Mark-approved knee repair product, GelrinC, with European surgeon training scheduled for Q3 2026."
datetime: "2026-06-17T14:40:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290071993.md)
  - [en](https://longbridge.com/en/news/290071993.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290071993.md)
---

# Why Is Regentis Biomaterials Stock Rising On Wednesday?

**Regentis Biomaterials Ltd.** (AMEX:RGNT), a regenerative medicine company stock, is trading higher on Wednesday following the official withdrawal of its proposed public share offering and accelerating commercial plans for its lead medical product.

## SEC Public Offering Withdrawal

Regentis Biomaterials filed an application with the Securities and Exchange Commission (SEC) to officially withdraw its Form F-1 registration statement, effective as of June 15. The company stated in the filing that it “has determined not to pursue the public offering to which the Registration Statement relates.”

The company had proposed a public offering of 3.33 million ordinary shares at an assumed price of $3 per share to raise roughly $10 million on June 1. The withdrawal eliminates the immediate potential for equity dilution associated with the proposed share issuance.

**Read Also: Stock Market Today: Dow Jones Futures Tumble, S&P 500 Gains As Investors Await FOMC Decision—Amkor, La-Z-Boy In Focus**

## European Commercialization Momentum

Market movement follows operational updates regarding the company’s core regenerative product, GelrinC, which is an off-the-shelf hydrogel implant designed for knee cartilage repair. The product has already received CE Mark approval in Europe.

## Strategic Timeline And Rollout

Management stated that it will initiate European surgeon training in the third quarter of 2026. This step solidifies the corporate timeline toward active commercial deployment and revenue readiness in European markets.

## Critical Levels To Watch for RGNT Stock

From a longer-term chart perspective, RGNT is still trying to recover from a rough 12 months (down 18.67%), but the near-term trend has flipped aggressively higher as the stock pushes deeper into the upper half of its 52-week range ($1.23 to $15.50). The current premarket price around $6.79 also keeps it well above key trend gauges: about 178% above the 20-day SMA ($2.45), about 160% above the 50-day SMA ($2.62), and about 103% above the 100-day SMA ($3.35).

One caution flag is that the 20-day SMA is still below the 50-day SMA, a bearish alignment that often shows the market is still working off earlier weakness despite the recent surge.

-   **Key Resistance**: $7.50
-   **Key Support**: $6

**RGNT Stock Price Activity:** Regentis Biomaterials shares were up 11.16% at $6.87 on Wednesday, according to Benzinga Pro data.

**Read Also: Perplexity's CEO Predicts Micron Could Overtake Meta In Stunning AI Power Shift: 'Whatever Is The Bottleneck Will…'**

_Photo: Shutterstock_

### Related Stocks

- [RGNT.US](https://longbridge.com/en/quote/RGNT.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [AMKR.US](https://longbridge.com/en/quote/AMKR.US.md)
- [LZB.US](https://longbridge.com/en/quote/LZB.US.md)
- [MU.US](https://longbridge.com/en/quote/MU.US.md)
- [META.US](https://longbridge.com/en/quote/META.US.md)

## Related News & Research

- [Regentis Biomaterials Shareholders Approve All Proposals at July 9 Adjourned AGM](https://longbridge.com/en/news/292243855.md)
- [Regentis Biomaterials adjourns annual shareholder meeting to July 9 after no quorum](https://longbridge.com/en/news/291586198.md)
- [07:57 ETEVERSANA Selected by Innovacell as Commercialization Partner to Advance Novel Cell Therapy ICEF15 in the United States](https://longbridge.com/en/news/294360419.md)
- [OPAL Fuels signs long-term deal to build, own Dinuba, California CNG/RNG station for municipal refuse fleet](https://longbridge.com/en/news/294361790.md)
- [12:50 ETThe Charming Taste of Europe Highlights Wine Tourism Through the Terroirs of Bordeaux and Abruzzo](https://longbridge.com/en/news/294236357.md)